Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia

Inclusion Criteria: * Homozygous Familial Hypercholesterolemia (HoFH) diagnosed by genetic confirmation * Fasting LDL-C \>130 mg/dL (3.4 mmol/L) at screening * On maximally tolerated dose of statin (investigator's discretion) with or without other lipid-lowering therapy; stable for ≥ 30 days before screening * Male or female participants \>=12 to \<18 years of age at screening Exclusion Criteria: * Documented evidence of a null (negative) mutation in both LDLR alleles * Heterozygous familial hypercholesterolemia (HeFH) * Active liver disease * Secondary hypercholesterolemia, e.g. hypothyroidism or nephrotic syndrome * Previous treatment with monoclonal antibodies directed towards PCSK9 (within 90 days of screening) * Treatment with mipomersen or lomitapide (within 5 months of screening) * Recent and/or planned use of other investigational medicinal products or devices